Revolution Medicines Initiates P-III (RASolute 303) Trial of Daraxonrasib in Pancreatic Ductal Adenocarcinoma (PDAC)

Why It Matters

A successful outcome would give Revolution Medicines a first‑in‑class RAS‑targeted therapy in PDAC, a market with high unmet need and significant revenue potential. The genotype‑agnostic approach also simplifies patient selection, accelerating adoption if efficacy is proven.

Key Takeaways

• Phase III RASolute 303 starts globally for untreated metastatic PDAC.
• Daraxonrasib targets active RAS (ON) across all genotypes.
• Primary endpoints: progression‑free and overall survival.
• Trial includes monotherapy and chemo‑combined arms.
• Daraxonrasib evaluated in three PDAC, one NSCLC Phase III trials.

Pulse Analysis

Targeting KRAS has long been a holy grail in oncology, with most agents failing to bind the active, GTP‑bound state of the protein. Revolution Medicines’ daraxonrasib distinguishes itself as a direct RAS(ON) multi‑selective inhibitor, capable of engaging multiple KRAS isoforms regardless of mutation status. This breakthrough chemistry could unlock therapeutic options for cancers where KRAS drives growth, especially pancreatic ductal adenocarcinoma, a disease that historically offers limited effective systemic treatments. By addressing the ‘undruggable’ RAS pathway, the drug positions itself at the forefront of precision oncology.

The RASolute 303 study enrolls previously untreated patients with metastatic PDAC and evaluates daraxonrasib both as monotherapy and in combination with standard chemotherapy. Primary endpoints focus on progression‑free survival and overall survival, while secondary measures capture objective response rates, safety, tolerability, and patient‑reported outcomes. Importantly, the trial does not stratify by KRAS mutation, reflecting the drug’s genotype‑agnostic mechanism and potentially broadening its eligible population. Such a design aligns with industry trends toward biomarker‑independent regimens that simplify enrollment and accelerate time‑to‑market.

The commercial stakes are equally high. Royalty Pharma recently acquired the worldwide royalty rights to daraxonrasib for roughly $2 billion, underscoring investor confidence in the drug’s revenue potential. If the Phase III data demonstrate a survival advantage, Revolution Medicines could secure a first‑in‑class position in a market projected to exceed $5 billion annually for pancreatic cancer therapies. Moreover, the concurrent NSCLC trial expands the addressable oncology portfolio, offering cross‑indication leverage that could amplify long‑term cash flow and justify the sizable upfront royalty outlay.